Please provide your email address to receive an email when new articles are posted on . Researchers found a median reduction in systolic blood pressure of 32 mm Hg. Results are consistent with ...
Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective, Dilraj Grewal, MD, discusses an analysis of the VISTA and VIVID studies ...
The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...
In a post-hoc analysis of the ADVANCE and MOTIVATE phase III induction studies, along with the FORTIFY maintenance study, researchers evaluated the safety profile of risankizumab (Skyrizi) in patients ...
In a post-hoc analysis of the DELIVER trial, interictal periods were longer with VYEPTI compared to placebo and corresponded to higher patient-reported quality of life outcomes Individuals taking ...
The findings suggest that treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) led to improvements and had a similar safety profile to both FF/VI and UMEC/VI regardless of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results